Sulfonylurea News and Research

RSS

How long should you take GLP-1 drugs? Study links longer use to lower heart risk

Continuous use of GLP-1 receptor agonists in adults with type 2 diabetes was associated with a lower risk of major cardiovascular events compared with sulfonylureas, with benefits increasing over time. Discontinuation or interruption was associated with a progressive loss of this protective effect, with risks approaching those of comparator therapy.

19 Mar 2026

Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit

A large cohort study of more than 600,000 US veterans with type 2 diabetes found that initiating GLP-1 receptor agonists was associated with lower risks of developing substance use disorders compared with SGLT-2 inhibitors. Among veterans with existing substance use disorders, GLP-1 receptor agonist use was also linked to fewer overdose events, hospitalizations, and suicide-related outcomes.

8 Mar 2026

SGLT-2 inhibitors offer protection against autoimmune conditions

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, compared with another group of diabetes drugs called sulfonylureas, finds a study from South Korea published by The BMJ today.

15 Oct 2025

Metformin’s blood sugar control starts in the brain, not just the liver, study finds

Low, clinically relevant doses of metformin lower blood glucose by inhibiting the Rap1 protein in specific neurons of the hypothalamus, revealing a brain-first mechanism. This action is essential for metformin’s effect at therapeutic doses and highlights new directions for diabetes treatment.

3 Aug 2025

Mortality risk higher for those diagnosed with type 2 diabetes at younger ages

Findings indicate younger-onset type 2 diabetes is associated with higher mortality and complications, highlighting the need for focused healthcare strategies.

4 Nov 2024

CKMT2 regulates mitochondrial function and energy metabolism in type 2 diabetes

Creatine kinase M2 (CKMT2) plays a key role in mitochondrial dysfunction in type 2 diabetes, affecting energy metabolism in skeletal muscle.

10 Oct 2024

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

Long-term sulfonylurea use linked to increased risk of hypoglycemia unawareness

Sulfonylureas are a class of oral medications used to manage blood glucose levels in patients with type 2 diabetes.

22 Jul 2024

Study reveals potential cognitive benefits of antidiabetic drugs

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.

12 Jul 2024

Scientific review explores adzuki beans' efficacy in diabetes prevention and management

Adzuki bean (Vigna angularis) supplementation to prevent and manage type 2 diabetes (T2D).

25 Jan 2024

How safe are GLP-1R agonists in early pregnancy?

JAMA Internal Medicine study examines the safety of GLP-1 receptor agonists and other second-line antidiabetic medications during early pregnancy, finding no significant increase in congenital anomalies compared to insulin use.

14 Dec 2023

Do glucose-lowering medications have different effects on kidney outcomes?

Researchers evaluated the kidney outcomes in individuals with type 2 diabetes.

26 May 2023

Cardiovascular risk reduction in type 2 diabetes: Study urges better use of life-saving therapies

Researchers explore the efficacy of current approaches to reduce the risk of cardiovascular events in patients with type 2 diabetes.

10 May 2023

Metformin may reduce the risk of osteoarthritis

In a recent study published in JAMA Network Open, researchers in the United States (US) determined the risk of osteoarthritis (OA) and joint replacement among adults with type 2 diabetes (T2D) following metformin or sulfonylurea treatment.

27 Mar 2023

Are SGLT2 inhibitors the next blockbuster drug?

Recent clinical trials investigating the therapeutic potency of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have highlighted that this drug is highly effective in treating patients with cardiovascular and renal diseases.

19 Feb 2023

Researchers identify a new pathogenic mechanism for diabetes onset in MODY3

In order to treat patients with diabetes in the best possible way it is necessary to understand the disease mechanism. MODY type 3 (MODY3) is a monogenic hereditary form of diabetes, that is caused by a genetic defect in the HNF1A gene.

22 Dec 2022

Metformin reduces risk of severe COVID-19 in diabetic patients

A new study determines whether antidiabetic agents can reduce complications in COVID-19 patients with diabetes.

10 Oct 2022

Researchers assess Alzheimer's disease risk and anti-diabetic drugs

In a new study, researchers assessed the genetic variation among targets of Alzheimer's disease risk and anti-diabetic drugs.

3 Aug 2022

$Insulin users at elevated risk of fractures compared to diabetic patients using metformin$

Insulin users at elevated risk of fractures compared to diabetic patients using metformin

Patients with type 2 diabetes have an increased risk for fractures, despite their normal-to-high bone mineral density, according to research being presented Saturday, June 11 at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

12 Jun 2022

Can metformin reduce mortality in diabetic individuals with severe COVID-19?

A new study by researchers in China and the U.S. describes a round-up of the effects of commonly used hypoglycemic drugs on the outcomes of COVID-19 in diabetic patients.

1 Feb 2021